Analysts Set OPKO Health, Inc. (NASDAQ:OPK) Target Price at $2.03

OPKO Health, Inc. (NASDAQ:OPK) has received a consensus rating of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $2.0333.

A number of research firms have issued reports on OPK. JPMorgan Chase & Co. assumed coverage on OPKO Health in a research note on Thursday, November 20th. They issued a “neutral” rating on the stock. Wall Street Zen lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Barrington Research reduced their price target on shares of OPKO Health from $2.25 to $1.50 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. World Investment Advisors increased its stake in OPKO Health by 63.8% during the fourth quarter. World Investment Advisors now owns 66,520 shares of the biotechnology company’s stock worth $84,000 after acquiring an additional 25,902 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of OPKO Health by 1,056.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 39,232 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 35,841 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of OPKO Health in the 4th quarter valued at approximately $145,000. EP Wealth Advisors LLC purchased a new position in shares of OPKO Health in the 4th quarter worth approximately $37,000. Finally, XTX Topco Ltd bought a new position in shares of OPKO Health during the 4th quarter valued at approximately $432,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Stock Performance

Shares of OPKO Health stock opened at $1.17 on Tuesday. The firm has a market cap of $888.11 million, a price-to-earnings ratio of -3.90 and a beta of 1.50. The business has a 50-day moving average price of $1.24 and a 200-day moving average price of $1.34. The company has a quick ratio of 3.52, a current ratio of 3.97 and a debt-to-equity ratio of 0.26. OPKO Health has a twelve month low of $1.11 and a twelve month high of $1.86.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The company had revenue of $148.50 million for the quarter, compared to the consensus estimate of $139.76 million. During the same period in the previous year, the business earned $0.01 earnings per share. The firm’s revenue for the quarter was down 19.1% on a year-over-year basis. Equities research analysts anticipate that OPKO Health will post -0.25 EPS for the current fiscal year.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.